AUTL AUTOLUS THERAPEUTICS PLC Investments/Divestments 8-K Filing 2024 - License and Option Agreement with BioNTech SE Autolus Therapeutics plc has entered into a License and Option Agreement with BioNTech SE, granting BioNTech an exclusive license to certain binders and the option to acquire additional rights to specified clinical-stage product candidates, binders, and technologies, with potential payments of up to $582 million.Get access to all SEC 8-K filings of the AUTOLUS THERAPEUTICS PLC